PD-L2 glycosylation promotes immune evasion and predicts anti-EGFR efficacy

Código QR

PD-L2 glycosylation promotes immune evasion and predicts anti-EGFR efficacy

Guardado en:

Detalles Bibliográficos
Autores principales:	Min Li, Yiqi Xu, Yuqing Wang, Xuan Zhou, Mei Mei, Jingxuan Yang, Zhenyue Gao, Ruxin Hu, Yuhong Wang, Zheng Su, Xiaoyue Zhang, Yu Ren
Formato:	article
Lenguaje:	EN
Publicado:	BMJ Publishing Group 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/f250465286994ea6abf8effc519ed749
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Clinical observation of the efficacy of PD‐1/PD‐L1 inhibitors in the treatment of patients with advanced solid tumors
por: Miao Wang, et al.
Publicado: (2021)

The long noncoding RNA lnc-EGFR stimulates T-regulatory cells differentiation thus promoting hepatocellular carcinoma immune evasion
por: Runqiu Jiang, et al.
Publicado: (2017)

Next generation of anti-PD-L1 Atezolizumab with enhanced anti-tumor efficacy in vivo
por: Maohua Li, et al.
Publicado: (2021)

STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion
por: Jung-Mao Hsu, et al.
Publicado: (2018)

Impact of EGFR mutation detection methods on the efficacy of erlotinib in patients with advanced EGFR-wild type lung adenocarcinoma.
por: Jeng-Sen Tseng, et al.
Publicado: (2014)

The folate cycle enzyme MTHFD2 induces cancer immune evasion through PD-L1 up-regulation
por: Man Shang, et al.
Publicado: (2021)

Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer
por: Dora Hammerl, et al.
Publicado: (2021)

PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy
por: Pottayil G. Sasikumar, et al.
Publicado: (2021)

Activity of PD-1 Inhibitor Combined With Anti-Angiogenic Therapy in Advanced Sarcoma: A Single-Center Retrospective Analysis
por: Yang You, et al.
Publicado: (2021)

Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis
por: Melissa L. Bastacky, et al.
Publicado: (2021)

PD-L1 expression as a predictor of postoperative recurrence and the association between the PD-L1 expression and EGFR mutations in NSCLC
por: Kensuke Kojima, et al.
Publicado: (2021)

The combination therapy of oncolytic HSV-1 armed with anti-PD-1 antibody and IL-12 enhances anti-tumor efficacy
por: Xin Xie, et al.
Publicado: (2022)

Potential Biomarkers for the Efficacy of PD-1-PD-L Blockade in Cancer
por: Grecea M, et al.
Publicado: (2021)

Anti-EGFR antibody 528 binds to domain III of EGFR at a site shifted from the cetuximab epitope
por: Koki Makabe, et al.
Publicado: (2021)

Acetylation in Tumor Immune Evasion Regulation
por: Jun Lu, et al.
Publicado: (2021)

Characterization of glycosyl dioxolenium ions and their role in glycosylation reactions
por: Thomas Hansen, et al.
Publicado: (2020)

Plasminogen Activating Inhibitor-1 Might Predict the Efficacy of Anti-PD1 Antibody in Advanced Melanoma Patients
por: Kentaro Ohuchi, et al.
Publicado: (2021)

Role of structure and glycosylation of adsorbed protein films in biolubrication.
por: Deepak H Veeregowda, et al.
Publicado: (2012)

Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer
por: Ken Uchibori, et al.
Publicado: (2017)

Disulfiram Improves the Anti-PD-1 Therapy Efficacy by Regulating PD-L1 Expression via Epigenetically Reactivation of IRF7 in Triple Negative Breast Cancer
por: Xin Zheng, et al.
Publicado: (2021)

Cinobufagin Is a Selective Anti-Cancer Agent against Tumors with EGFR Amplification and PTEN Deletion
por: Kunyan He, et al.
Publicado: (2021)

Epitope Shaving Promotes Fungal Immune Evasion
por: Delma S. Childers, et al.
Publicado: (2020)

Author Correction: Anti-inflammatory effect of afatinib (an EGFR-TKI) on OGD-induced neuroinflammation
por: Yen-Ju Chen, et al.
Publicado: (2021)

Tumor-specific delivery of therapeutic siRNAs by anti-EGFR immunonanoparticles
por: Kim JS, et al.
Publicado: (2018)

Comparison of the Prognostic Value of Inflammation-Based Scores in Patients with Hepatocellular Carcinoma After Anti-PD-1 Therapy
por: Mei J, et al.
Publicado: (2021)

A Novel Bispecific Antibody Targeting PD-L1 and VEGF With Combined Anti-Tumor Activities
por: Xiaopei Cui, et al.
Publicado: (2021)

Regulation of Tripartite Motif-Containing Proteins on Immune Response and Viral Evasion
por: Xiu-Zhong Zhang, et al.
Publicado: (2021)

Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
por: Hyun Tae Lee, et al.
Publicado: (2017)

Cost-Effectiveness of Ipilimumab Plus Anti-PD-1 Therapy Versus Ipilimumab Alone in Patients With Metastatic Melanoma Resistant to Anti-PD-(L)1 Monotherapy
por: Ye Peng, et al.
Publicado: (2021)

Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
por: Wen M, et al.
Publicado: (2018)

CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells
por: Levi J. Rupp, et al.
Publicado: (2017)

A nanoscale metal organic frameworks-based vaccine synergises with PD-1 blockade to potentiate anti-tumour immunity
por: Xia Li, et al.
Publicado: (2020)

SNAIL1: Linking Tumor Metastasis to Immune Evasion
por: Xiaolong Tang, et al.
Publicado: (2021)

ARIH1 signaling promotes anti-tumor immunity by targeting PD-L1 for proteasomal degradation
por: Youqian Wu, et al.
Publicado: (2021)

Synergistic effects of AAGL and anti-PD-1 on hepatocellular carcinoma through lymphocyte recruitment to the liver
por: Xiangdong Ye, et al.
Publicado: (2021)

Targeting colorectal cancer with human anti-EGFR monoclonocal antibodies: focus on panitumumab
por: George P Kim, et al.
Publicado: (2008)

NEK2 inhibition triggers anti-pancreatic cancer immunity by targeting PD-L1
por: Xiaozhen Zhang, et al.
Publicado: (2021)

Blocking autophagy improves the anti-tumor activity of afatinib in lung adenocarcinoma with activating EGFR mutations in vitro and in vivo
por: Xiangxiang Hu, et al.
Publicado: (2017)

Notch signaling and efficacy of PD-1/PD-L1 blockade in relapsed small cell lung cancer
por: Nitin Roper, et al.
Publicado: (2021)

TRAPPC4 regulates the intracellular trafficking of PD-L1 and antitumor immunity
por: Yimeng Ren, et al.
Publicado: (2021)